Welcome to BioSeeker Group!

Complete Target Atlas in Oncology Drug Development: From Tumor to Targeted Therapy

Additional Information

Pages 2399
Published on Date Multi-report (See individual release dates)
Format PDF
Publisher BioSeeker Group

Availability: In stock

$7,950.00

Quick Overview

This report is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of cancer drugs. It will assist you in lead commercial analysis and product strategy thinking to build and nurture current and future portfolio of drug candidates and R&D alliances.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Complete Target Atlas in Oncology Drug Development: From Tumor to Targeted Therapy.

    To find out more about Complete Target Atlas in Oncology Drug Development: From Tumor to Targeted Therapy, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Complete Target Atlas in Oncology Drug Development: From Tumor to Targeted Therapy is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

With the emergence of new technologies and an increased understanding of the biological basis for cancer evolution, the molecular changes that distinguish malignant-cells from normal cells are becoming increasingly apparent, offering a growing range of potential drug targets in the form of altered genes, proteins or corrupted pathways. Drug targets are the critical link between drugs and their role in the treatment of medical disorders.

This report, Complete Target Atlas in Oncology Drug Development, is written for you to identify your competition and understand which targeting strategies are at work within the cancer drug development landscape. It allows you to pin-point which competitors drugs’ clinical out-come may have bearing on your own drug development and who are developing sequels to successful drugs. This report also helps you to locate white-spots in the competitive landscape, giving you little or no competition. Conversely it may reveal unexpected competition for you.

Complete Target Atlas in Oncology Drug Development is a multi-report made up by nine different and independent target reports covering five different targeted therapies areas and four major tumor types in detail:

Targeted Therapy Strategies in Cancer:
Apoptosis
Angiogenesis/VDA/VTA
Immunomodulators & Vaccines
Protein Kinase Inhibitors

Major Tumor Types:
Breast Cancer
Melanoma
Colorectal Cancer
Antibodies
Prostate Cancer

Each report subject covers:
- Compound strategies based on sub-cellular localization of cancer drug targets
- The Cancer Genome Project and cancer drug targets
- Expression levels of identified drug targets in selected tumor type
- Pathway analysis of cancer drug targets
- Target-target interactions among identified cancer targets
- Structure-based drug design in ‹s stimulated by available structure data on biological targets
- Unique, in-depth, drug target validating profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other cancer drug targets, pursued cancer indications, drugs under development, presence in the Cancer Genome Project etc.
- Drug-target interactome
- The progression and maturity of cancer targets: New and unique cancer drug targets
- Indication specific reports deal with targets by R&D approach in specified cancer types, whereas targeted therapy specific reports deal with targets by cancer indication.
- Cancer drug target profiles by investigator
- The progression and maturity of cancer targets: New and unique cancer drug targets
- Indication specific reports deal with targets by R&D approach in specified cancer types, whereas targeted therapy specific reports deal with targets by cancer indication.
- Cancer drug target profiles by investigator

This report is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of cancer drugs. It will assist you in lead commercial analysis and product strategy thinking to build and nurture current and future portfolio of drug candidates and R&D alliances. This report will help you to streamline your analysis of new as well as of established drug targets, when looking for clinical proofs, indication selection, competitive environment etc.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Complete Target Atlas in Oncology Drug Development: From Tumor to Targeted Therapy.
    To find out more about Complete Target Atlas in Oncology Drug Development: From Tumor to Targeted Therapy, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Complete Target Atlas in Oncology Drug Development: From Tumor to Targeted Therapy is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Oncology' category:


Triple Analysis: Lung Cancer, Lymphoma and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Lymphoma and by the mechanism/target/effect of Cancer Vaccines. Learn More


Target Atlas in Prostate Cancer: A Competitive Outlook
System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
- Browser Application (Internet Explorer)
- Internet access (to access related internet resources)
Learn More

Other selected research from the 'Targeted' category:


Competitive Outlook on Antiangiogenesis and Vascular Targeting in Oncology
Assess opportunities and risks for the continued development of anti-angiogenic and vascular targeting agents in five major cancer indications. Learn More


Complete Target Atlas in Oncology Drug Development: From Tumor to Targeted Therapy
This report is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of cancer drugs. It will assist you in lead commercial analysis and product strategy thinking to build and nurture current and future portfolio of drug candidates and R&D alliances. Learn More